Ali Mortazavi, e-Therapeutics CEO, explains how the company’s tech will be used by Nasdaq-listed iTeos in its latest collaboration with a leading pharma group.
e-Therapeutics can model almost any biological process or function within any disease area, he says, and iTeos wants to use its platform to work on immunotherapy-based cancer treatments.
iTeos is just the latest in a number of big-name pharma partners that are using its tech, he adds.